Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SACUBITRIL AND VALSARTAN
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
- A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- Initiation of ARNi and SGLT2i in Patients With HFrEF
- Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
- Sacubitril/Valsartan Versus Valsartan in Heart Failure
- Angiotensin Receptor-Neprilysin Inhibitor After Transcatheter Aortic Valve Implantation
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
- Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
- Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
- The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
- Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
- Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
- Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
- Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
- Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
- Sacubitril/Valsartan for CKD5 Stage Dialysis Patients With Heart Failure
- Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
- Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)
- ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
- The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF
- Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
- Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome
- Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.
- The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
- Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
- Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
- Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension
- Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
- The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure
- Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
- Sacubitril/Valsartan in Resistant Hypertension
- Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
- The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
- Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure
- Early Treatment of ARNI on Myocardial Remodeling and Progress
- NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
- Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output
- Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD
- Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
- Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
- Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
- Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI
- Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
- Sacubitril/Valsartan in Left Ventricular Assist Device Recipients
- Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
- NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
- Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
- Changes in NT-proBNP and Outcomes, Safety, and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
- LCZ696 in Advanced LV Hypertrophy and HFpEF
- COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
- An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
- The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction
- Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
- Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure
- Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation
- CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
- Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure
- Prevention of Cardiac Dysfunction During Breast Cancer Therapy
- Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin
- The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
- Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
- Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
- Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure
- The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
- Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
- The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure
- Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
- Comparing ARNI With ACE Inhibitor on Endothelial Function
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
- Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
- PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
- Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
- randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
- Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
- Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
- EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
- Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
- Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
- Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
- Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
- Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
- Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
- Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Clinical trials list
click for details